Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

PURPOSE: Metformin, widely used as antidiabetic drug, showed antitumoral effects expecially in combination with chemotherapy. Our group recently has demonstrated that metformin and gefitinib are synergistic in LKB1-wild-type NSCLC cells. In these models, metformin as single agent induced an activati...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Della Corte, Carminia Maria, Ciaramella, Vincenza, Mauro, Concetta Di, Castellone, Maria Domenica, Papaccio, Federica, Fasano, Morena, Sasso, Ferdinando Carlo, Martinelli, Erika, Troiani, Teresa, De Vita, Ferdinando, Orditura, Michele, Bianco, Roberto, Ciardiello, Fortunato, Morgillo, Floriana
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2015
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826204/
https://ncbi.nlm.nih.gov/pubmed/26673006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6559
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items